Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63,492,063
-
Total 13F shares
-
36,470,008
-
Share change
-
+35,816,136
-
Total reported value
-
$190,106,000
-
Price per share
-
$5.25
-
Number of holders
-
22
-
Value change
-
+$182,848,000
-
Number of buys
-
22
-
Number of sells
-
1
Institutional Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q2 2022
As of 30 Jun 2022,
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,470,008 shares.
The largest 10 holders included
BVF INC/IL, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, FMR LLC, TCG Crossover Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., RTW INVESTMENTS, LP, GREAT POINT PARTNERS LLC, and TANG CAPITAL MANAGEMENT LLC.
This page lists
22
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.